Table 1.

Biomedical Applications of LC separation strategies for MS based glycomics

LC-Strategy	Biomedical Application	Ref.
HILIC
ZIC®-HILIC	2-AP human serum IgG N-glycans	[44]
ZIC®-HILIC	Aniline labeled sialylated N-glycans from human AGP	[45]
ZIC®-HILIC	2-AB labeled N-glycans from recombinant mAbs	[46]
Amide/Amine	Aniline labeled N-glycoforms of chicken and pheasant ovotransferrin	[47]
Amide/Amine	2-AP labeled IgG N-glycans	[48]
Amide/Amine	2-AB labeled serum N-glycans for identification of cancer-associated alterations in glycosylation	[49]
Amide/Amine	2-AB labeled N-glycans from keyhole limpet hemocyanin, asialofetuin and RNase B	[58]
Amide/Amine	DMT/MM and 2-AB labeled N-glycans released from haptoglobin and human plasma (development), and sera from patients with lung, breast, ovarian, pancreatic, or gastric cancer.	[53]
fused-silica penta	Procainamide labeled N-glycans from fetuin and human serum	[54]
RPLC
C18	ANTS derivatized N-glycans from fetuin, RNase B and chicken ovalbumin	[82]
C18	Permethylated glycan alditols from fusion protein MUC1-S expressed in EBNA-293 cells	[90]
C18/PGC	Reduced and permethylated free oligosaccharides and N-glycans from human, bovine, and goat milk	[23]
C18	Reduced and permethylated N-glycans from human blood serum for the identification of biomarkers associated with hepatocellular carcinoma	[63]
C18	Reduced and permethylated N-glycans released from RNase B, porcine thyroglobulin, and pooled male human blood serum	[66]
C18	Reduced and permethylated N-glycans released from neuroblastoma cell lines (MYCN-nonamplified SY5Y and MYCN-amplified NLF)	[35]
C18	Reduced and permethylated N-glycans released from ipsilateral cortical brain tissues	[75]
C18	Reduced and permethylated N-glycans released from glioma stem cell xenografts	[76]
C18	Reduced and permethylated N-glycans released from brain-targeting breast carcinoma cells (MDA-MB-231BR) and metastatic breast cancer cells (MDA-MB-231)	[77]
HPAEC
CarboPac PA200	N-glycans released from glycoproteins of the human SKOV3 ovarian carcinoma cell line	[104]
CarboPac PA200	Isomeric Fc N-linked glycans of the heterogeneously glycosylated mAb IgG1	[33]
CarboPac PA1	Oligosaccharides in lignocellulosic biomass hydrolysates	[105]
CarboPac PA-10	Qualitative and quantitative analysis of dextran branching patterns	[106]
Vydac301VHP57/NPLC/C18	Sialylated N-glycans in adult rat brain tissue	[137]
GlycoSep C/Amine/Amine	Complex N-glycans present on the European Biological Reference Preparation 3 EPO standard	[111]
PGC
PGC	N-glycans released from RNase B	[120]
PGC/C18	Reduced and permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma and cirrhosis patients	[78]
PGC	N-glycans released from human EPO from CHO cells	[121]
PGC	Reduced native N- and O-linked oligosacchides derived from mucin glycoproteins	[122]
PGC	Reduced N-glycans derived from mammalian fibrin	[123]
PGC	N-glycans derived from bovine thyroid stimulating hormone, fibrin, fetuin, and recombinant EPO and 4E10 from CHO cells	[32]
PGC	N-glycan alditols released from membrane proteins from serous ovarian cancer cell lines (SKOV 3, IGROV 1, A2780, and OVCAR 3) and non-cancerous ovarian surface epithelial cell lines (HOSE 6.3 and HOSE 17.1)	[124]
PGC	Human milk DMBA oligosaccharides	[128]
PGC	Kidney N-glycans in a mouse model of systemic lupus erythematosus	[138]
PGC	Reduced and permethylated malto-oligosaccharides, N-glycans released from RNase B and articular cartilage and O-glycans released from C. elegans	[131]
PGC	Reduced and permethylated N-glycans released from fetuin, RNase B, IgG and pooled human blood serum.	[23]
PGC	Reduced and permethylated N-glycans released from fetuin, RNase B and the two breast cancer cell lines MDA-MB-231 and MDA-MB-231BR.	[132]
PGC	Methylamidated sialylated N-glycans released from bovine and human serum	[135]
PGC chip	Native glycans derived from two groups of prostate cancer patients with different prognoses	[125]
PGC chip	N-glycans released from dried human blood spots	[126]